183 387

Cited 0 times in

Survival outcomes of concurrent treatment with docetaxel and androgen deprivation therapy in metastatic castration-resistant prostate cancer

Other Titles
 Docetaxel 치료를 받는 전이 거세저항성 전립선암 환자에서 남성호르몬 박탈치료 유지의 효과 
Issue Date
Dept. of Medicine/석사
Introduction: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we aimed to assess the impact of combined use of androgen deprivation therapy (ADT) with DTX for mCRPC.

Materials and Methods: We performed a single-institutional retrospective analysis of patients with mCRPC who received either DTX alone (DTX group, n=21) or concurrent DTX and ADT (DTX+ADT group, n=26) between August 2006 and February 2014. All patients received DTX dosed 75 mg/m2 every three weeks for at least three cycles. In the DTX+ADT group, all patients used luteinizing hormone releasing hormone agonist continuously as a concurrent ADT.

Results: The median follow-up period was 24.0 months (IQR 12.0–37.0) for the entire cohort. The median radiographic progression-free survival (rPFS) was 9.0 months and 6.0 months in the DTX+ADT and DTX groups, respectively (log-rank p=0.036). In multivariable Cox regression analysis, concurrent administration of ADT was the only significant predictor of rPFS (HR=0.525, 95% CI 0.284-0.970, p=0.040). The median OS was 42.0 and 38.0 months in the DTX+ADT and DTX groups, respectively (log-rank p=0.796). On multivariable analysis, Hb level at the time of DTX initiation was associated with OS (HR=0.532, 95% CI 0.381-0.744, p<0.001).

Conclusions: In chemotherapy-naive patients with mCRPC, the combined use of ADT with DTX improved rPFS. Our result suggests that the concurrent administration of ADT and DTX is superior to DTX alone.
Files in This Item:
T014154.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 2. Thesis
Yonsei Authors
Jang, Ho Seong(장호성)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.